These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 22465063)
41. Sphingosine-1-phosphate modulates vascular permeability and cell recruitment in acute inflammation in vivo. Roviezzo F; Brancaleone V; De Gruttola L; Vellecco V; Bucci M; D'Agostino B; Cooper D; Sorrentino R; Perretti M; Cirino G J Pharmacol Exp Ther; 2011 Jun; 337(3):830-7. PubMed ID: 21421740 [TBL] [Abstract][Full Text] [Related]
42. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator. Tran JQ; Hartung JP; Peach RJ; Boehm MF; Rosen H; Smith H; Brooks JL; Timony GA; Olson AD; Gujrathi S; Frohna PA J Clin Pharmacol; 2017 Aug; 57(8):988-996. PubMed ID: 28398597 [TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Brossard P; Derendorf H; Xu J; Maatouk H; Halabi A; Dingemanse J Br J Clin Pharmacol; 2013 Dec; 76(6):888-96. PubMed ID: 23594176 [TBL] [Abstract][Full Text] [Related]
44. Modeling the Effect of the Selective S1P Lott D; Krause A; Seemayer CA; Strasser DS; Dingemanse J; Lehr T Pharm Res; 2017 Mar; 34(3):599-609. PubMed ID: 28028771 [TBL] [Abstract][Full Text] [Related]
45. Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis. Kruger TM; Valenzuela B; Thompson CD; Ouwerkerk-Mahadevan S; Ruixo JJP Clin Pharmacokinet; 2023 Nov; 62(11):1533-1550. PubMed ID: 37776485 [TBL] [Abstract][Full Text] [Related]
46. The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling. Ohno T; Hasegawa C; Nakade S; Kitagawa J; Honda N; Ogawa M Biopharm Drug Dispos; 2010 Oct; 31(7):396-406. PubMed ID: 20623701 [TBL] [Abstract][Full Text] [Related]
47. Ponesimod, a selective sphingosine 1-phosphate (S1P Dash RP; Rais R; Srinivas NR Xenobiotica; 2018 May; 48(5):442-451. PubMed ID: 28489480 [TBL] [Abstract][Full Text] [Related]
48. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. van Oosten BW; Rep MH; van Lier RA; Scholten PE; von Blomberg BM; Pflughaupt KW; Hartung HP; Adèr HJ; Polman CH J Neuroimmunol; 1996 May; 66(1-2):49-55. PubMed ID: 8964913 [TBL] [Abstract][Full Text] [Related]
49. Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects. Hwang I; Lee SW; Oh J; Lee S; Jang IJ; Yu KS Front Pharmacol; 2022; 13():930615. PubMed ID: 36071831 [No Abstract] [Full Text] [Related]
50. [A systematic study of the significance of lipoids in blood coagulation. II. The effect of the diaminophosphatides and their degradation product sphingosine]. HECHT E Acta Haematol; 1953 Apr; 9(4):237-52. PubMed ID: 13064995 [No Abstract] [Full Text] [Related]
51. Sphingosine as an inhibitor of blood clotting. HECHT E; SHAPIRO D Science; 1957 May; 125(3256):1041-2. PubMed ID: 13432756 [No Abstract] [Full Text] [Related]
60. Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage. Khan SA; Goliwas KF; Deshane JS Front Physiol; 2021; 12():760638. PubMed ID: 34690821 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]